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Abstract
Mesenchymal stem cells are heterogenous adult multipotent stromal cells that
can be isolated from various sources including: bone marrow, peripheral blood,
umbilical cord blood, dental pulp, and adipose tissue. They have certain immuno-
modulatory, immunosuppressive, and antimicrobial properties that enable them to
have several therapeutic and clinical applications including: treatment of autoim-
mune disorders, role in hematopoietic stem cell transplantation and regenerative
medicine, as well as treatment of various infections and their associated complica-
tions such as septic shock and acute respiratory distress syndrome. Although more
success has been achieved in preclinical trials on the use of mesenchymal stem cells
in animal models than in human clinical trials, particularly in septic shock and
Chagas disease, more progress has been made in both disorders after the recent use
of specific sources and certain doses of mesenchymal stem cells. Nevertheless, the
utilization of this type of stem cells has shown remarkable progress in the treatment
of few infections such as tuberculosis. The clinical application of mesenchymal stem
cells in the treatment of several diseases still faces real challenges that need to be
resolved. The following book chapter will be an updated review on the role of
mesenchymal stem cells in various infections and their complications.
Keywords: mesenchymal stem cells, host immunity, antimicrobial properties,
septic shock,Mycobacterium tuberculosis, Chagas disease,
human immunodeficiency virus
1. Introduction to mesenchymal stem cells
Mesenchymal stem cells (MSCs), which were first described by Alexander
Fridenstein in the 1960s, are heterogeneous, non-hematopoietic, adult multipotent
stromal progenitor cells that are capable of self-renewal as well as differentiation
into multiple lineages and various cell types [1–8]. They can be isolated from several
sources including bone marrow (BM), peripheral blood (PB), umbilical cord blood
(UCB), amniotic fluid, placenta, adipose tissue (AT), and dental pulp as shown
in Table 1 [1–8]. Although the BM is the main source of MSCs, these stromal
cells constitute only a small fraction of the total number of cells populating the
BM [2, 4–6].
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MSCs have the following distinguishing features: (1) ability to adhere to the plastic
vessel under optimal culture conditions; (2) capability to differentiate into osteoblasts,
adipocytes, and chondrocytes; and (3) having characteristic immunophenotypic pro-
file on flow cytometry [1–3, 5, 6, 8, 9]. MSCs are characteristically positive for: CD
105, CD 73, and CD 90 and characteristically negative for the following surface
1 Bone marrow
2 Peripheral blood
3 Umbilical cord blood: Wharton’s jelly
4 Placenta: chorionic villi of placenta
5 Amniotic fluid
6 Menstrual blood
7 Fallopian tubes and cervical tissue
8 Breast milk
9 Adipose tissues: fat
10 Dental pulp, periodontal ligaments, and exfoliated deciduous teeth
11 Palatal tonsils
12 Salivary glands
13 Skeletal muscle tissues
14 Dermal tissues
15 Lung tissues and alveolar epithelium
16 Liver tissues: fetal liver
17 Synovial membrane and fluid
18 Parathyroid glands
Table 1.
Sources of mesenchymal stem cells.
Positive Negative
Characteristic surface markers CD 105
CD 73
CD 90
CD 45
CD 34
CD 14
CD 11b
CD 19
CD 79a
HLA-DR
Other surface markers that may/may not be expressed CD 117
CD 166
CD 29
CD 44
CD 106
CD 9
CD 10
CD 13
CD 28
CD 33
CD 49b
CD 71
CD 164
CD 271
HLA-class I
Stro-1
SSEA-4
ITGA-11
CD 31
CD 33
CD 133
MSCs, mesenchymal stem cells; HLA, human leukocyte antigen.
The bold values are to differentiate characteristic from non-characteristic surface markers.
Table 2.
Surface markers of MSCs on Flow cytometry.
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markers: CD 45, CD 34, CD 11b, CD 14, CD 19, CD 79a, and HLA-DR. However,
certain types of MSCs can occasionally show positivity or negativity for specific
surface markers as shown in Table 2 [1–3, 5, 6, 8–14]. Also, MSCs can differentiate
into other cell types including: myocytes, cardiomyocytes, and neurons [5].
Several studies have shown that MSCs obtained from BM, AT, and other sources
do express CD 34 surface markers [4, 15–18]. MSCs can be seen in abundant
numbers in the circulation under the following circumstances: stem cell mobiliza-
tion with growth factors, tissue injuries, stroke, hypoxia, and inflammatory condi-
tions [4, 19–24]. Despite the efforts displayed over the last five decades including
identification of nine transcriptional factors, little is known about the molecular
basis underlying the stemness of MSCs and it is still unclear whether these recently
discovered genes regulate stemness or only differentiation of MSCs [7].
2. Functions, properties, and therapeutic indications of MSCs
MSCs have immunomodulatory and immunosuppressive properties that enable
them to have several therapeutic and clinical applications including: hematopoietic
stem cell transplantation (HSCT), autoimmune disorders, regenerative medicine
and tissue repair, neurological diseases, bone and cartilage disorders, as well as
treatment of several infections and acute respiratory distress syndrome (ARDS).
Details are shown in Table 3 [1, 2, 6, 8, 25–29]. MSCs are major constituents of the
BM microenvironment and the HSC niche and apparently they are the masters of
1.Hematopoietic stem cell transplantation:
a. Enhancement of engraftment
b. Prevention of graft versus host disease (GVHD)
c. Treatment of GVHD
2.Treatment of autoimmune diseases:
a. Systemic lupus erythromatosus
b. Rheumatoid arthritis
c. Systemic sclerosis
d. Type 1 diabetes mellitus
e. Multiple sclerosis
f. Crohn’s disease
3.Regenerative medicine and tissue repair:
a. Myocardial ischemia
b. Cardiac dysfunction
c. Chronic non-healing wounds
d. Liver injury
e. Myocardial infarction
f. Dilated cardiomyopathy
g. Critical limb ischemia
h. Spinal cord injuries
4.Treatment of various infections:
a. Bacterial infections including sepsis and its associated acute respiratory distress syndrome
b. Viral infections such as human immunodeficiency virus, hepatitis B and C viruses
c. Parasitic infections such as Chagas disease, schistosomiasis, and malaria
d. Mycobacterial infections such as tuberculosis
5.Other indications:
a. Macular degeneration, corneal reconstruction and transplantation
b. Bones and joints: osteogenesis imperfecta, osteoarthritis, and osteoporosis
c. Cancer gene therapy
d. Amyotrophic lateral sclerosis
e. Liver cirrhosis
Table 3.
Current and potential therapeutic indications for mesenchymal stem cells.
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survival and clonality [30–32]. The main functions of MSCs include: formation
of hematopoietic microenvironment, modulation of the activity of the immune
system, and regulating cell trafficking [33].
3. Role of MSCs in host defense and infections
The putative roles of BM-MSCs during infection are: (1) detection of pathogens,
(2) activation of host immune responses, (3) elimination of pathogens, (4) induc-
tion of proinflammatory gradients, and (5) modulation of proinflammatory host
immune response due to having specific immunoregulatory properties of MSCs
including: inhibition of differentiation of monocytes to dendritic cells (DCs), alter-
ation of cytokine profile of DCs, induction of tolerant phenotypes of naïve and
effector T-cells, inhibition of antibody production by B-cells, and suppression of
natural killer (NK) cell proliferation and NK-mediated cytotoxicity [1, 2, 28, 34].
BM-MSCs may augment antimicrobial responses, abridge proinflammatory and
damage responses, and ameliorate associated tissue injury and they appear to func-
tion as a critical fulcrum providing balance by promoting pathogen clearance during
the initial inflammatory response, and suppressing inflammation to preserve integ-
rity of the host and facilitate tissue repair [1, 2, 34].
The immunomodulatory properties of MSCs are mediated by cell-to-cell inter-
action and the secreted cytokines [35–37]. MSCs could potentially be involved at
multiple levels in host defense by mobilizing immune effector cells and modulation
of proinflammatory immune responses to minimize tissue damage [1, 37]. BM-
MSCs may protect against infectious challenge by direct effects on the pathogens or
through indirect effects on the host [1]. However, placenta-derived MSCs and fetal
membrane-derived MSCs are highly susceptible to herpes viruses including vari-
cella zoster virus (VZV) [2, 38]. Several types of stem cells including BM-MSCs and
neural stem cells can cross the blood brain barrier and reach not only brain tumors
but also ischemic and injured tissues caused by certain infections in the brain and
engraft there. Consequently, MSCs can be utilized as means of cellular carriers to
deliver therapeutic agents to sites of brain injury in order to exert their therapeutic
and tissue regenerative effects in the brain [39–43].
4. Antimicrobial properties of MSCs
MSCs have been shown to exhibit the following antimicrobial properties:
(1) capacity to enhance antibacterial activity by interaction with the host innate
immune system in order to increase antibiotic sensitivity, increase bacterial
killing, and slow bacterial growth; (2) capacity to enhance bacterial clearance in
preclinical models of sepsis, cystic fibrosis, and ARDS; and (3) secretion of
antimicrobial peptides such as: interleukin (IL)-17, indoleamine 2,3-dioxygenase
(IDO), β-defensins, lipocalin-2, and cathelicidin LL-37 [44–46]. Members of the che-
mokine family have been found to have antimicrobial peptide activity although the
role of chemokines in immunity during infection is rather complicated [47].
5. MSCs in sepsis, ARDS, and chronic bacterial infections
5.1 MSCs in sepsis syndrome and septic shock
Sepsis syndrome and septic shock represent major health problems worldwide and
they are leading causes of death in hospitalized patients due to their association with
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high rates of morbidity and mortality in the absence of effective therapy [48–51].
Sepsis is a potentially lethal syndrome that can develop following an infection in
which a breakdown in the immune homeostasis results in both proinflammatory and
anti-inflammatory mechanisms that become uncoupled from normal regulation [50].
The inflammatory-driven maladaptive response induces disruption of endothelial and
epithelial barriers, thus resulting in organ dysfunction. However, the host responds to
sepsis by stimulating the proliferation of HSCs in the BM or by activating emergency
hematopoiesis in an attempt to counteract the effects of sepsis on the function of
multiple body organs [51]. Septic shock is a devastating complication of uncontrolled
bacterial infection that carries a mortality rate of 20–50% [50, 52]. Currently, there is
no specific treatment for septic shock and the management of this devastating com-
plication of serious infections remains supportive. However, the following measures
should be taken into consideration: early identification, fluid resuscitation, prompt
institution of antibiotic therapy, control of the source of infection, circulatory sup-
port, and lung protection by mechanical ventilation [48, 49, 52, 53].
Based on numerous preclinical studies, cell-based therapies are potentially bene-
ficial in the treatment of septic shock and ARDS. However, various types of stem cells
including embryonic stem cells, MSCs, and induced pluripotent stem cells have been
used in the treatment of sepsis and ARDS, but MSCs are the most commonly used
stem cells in septic shock [53]. In patients with septic shock complicated by acute
lung injury (ALI) and ARDS, the paracrine factors secreted by MSCs can: mediate
endothelial and epithelial permeability, and increase alveolar fluid clearance in addi-
tion to other mechanisms that reduce the complications of septic shock [54].
In a mouse model of sepsis, lipopolysaccharide-preconditioned MSC transplan-
tation has been shown to: ameliorate survival rate after transplantation, protect cells
from apoptosis and organ damage, and have immunomodulatory therapeutic prop-
erties [55]. Also, transplanted MSC can secrete Toll-like receptor-4, which plays a
seminal role in attenuating in vivo Escherichia coli-induced pneumonia and ALI
through anti-inflammatory and antibacterial effects [56]. In experimental animal
models of sepsis, the effectiveness of BM-MSCs was compared to that of Wharton’s
jelly (WJ) of umbilical cord; both sources of MSCs regulated leukocyte trafficking
and reduced organ dysfunction but only WJ-MSCs were able to improve bacterial
clearance and survival [57]. In animal models of Staphylococcal toxic shock syn-
drome, MSCs; particularly AT derived MSCs; were able to suppress cytokine pro-
duction and attenuate sepsis but they failed to improve survival [58, 59].
Several preclinical sepsis studies have suggested that MSCs are capable of:
modulating inflammation, enhancing clearance of pathogens as well as tissue
repair, thus resulting in improvement in symptoms and reduction in organ damage and
finally improvement in survival and reduction in mortality rates [48–50, 52]. Ameta-
analysis that evaluated the preclinical use of MSCs in animal models of septic shock
demonstrated that MSC treatment significantly reducedmortality rates and the results
of this survey supported the decision to proceed to clinical trials that test the effective-
ness of MSCs in treating infections causing sepsis in humans [60].
In a phase I clinical trial that included patients admitted to the intensive care
unit (ICU) with septic shock, infusion of freshly cultured allogeneic BM-MSCs in
doses up to 3 million cells/kg into these ICU patients was shown to be safe as this
dose of stem cells did not exacerbate the elevated cytokine levels in the plasma of
patients with septic shock [52, 61].
5.2 MSCs in ALI and ARDS
Bacterial pneumonia and sepsis from non-pulmonary causes are the most com-
mon etiologies of ALI and ARDS that are associated with mortality rates ranging
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between 25 and 50% [62–65]. Management of ARDS is mainly supportive with:
protective ventilation, fluid conservation, and antimicrobial therapy [62, 64]. In
patients with bacterial pneumonia and sepsis, MSCs can attenuate inflammatory
process and enhance bacterial clearance [63, 65]. MSCs secrete paracrine factors
that can regulate lung permeability and decrease inflammation and this makes
MSCs a potentially attractive therapeutic modality for ALI [62]. In patients with
ARDS, MSCs can exert beneficial effects by secreting paracrine factors,
microvesicles, and transfer of mitochondria. These secretory products have: (1)
anti-inflammatory properties that participate in resolving injuries to lung endothe-
lium and alveolar epithelium; (2) regulatory effects on alveolar fluid clearance, thus
reducing lung edema; (3) antimicrobial effects mediated by release of antimicrobial
factors; and (4) upregulation of monocyte/macrophage phagocytosis [66]. In
Escherichia coli-injured human lungs, MSCs were able to: restore alveolar fluid
clearance, reduce inflammation, and exert antimicrobial activity partly through
secretion of keratinocyte growth factor [62].
In patients with bacterial pneumonia causing ALI and ARDS, MSCs could
become a promising novel therapeutic modality and an ideal candidate for future
cellular therapy due to the following reasons: (1) MSCs are able to differentiate into
various cell types, (2) MSCs can secrete multiple bioactive molecules that are
capable of stimulating recovery of injured cells and inhibiting inflammation, (3)
MSCs lack immunogenicity, and (4) MSCs can perform immunomodulatory func-
tions [62, 63, 65, 67]. In a phase I clinical trial, Jennifer Wilson et al. showed safety
of allogeneic BM-MSCs administered to patients with ARDS [56, 68]. However, the
role of MSCs in ARDS patients should be carefully evaluated by well-designed
multicenter randomized clinical trials [68].
5.3 MSCs in severe and chronic infections
Chronic implant and wound infections that are characterized by biofilm forma-
tion are often difficult to treat and they usually require continuous antibiotic ther-
apy for weeks to months. However, alternative therapies for chronically infected
wounds include: use of antibiotic impregnated implant materials or biological scaf-
folds, administration of biofilm disrupting agents, and combining cellular immu-
notherapy with antibiotics [44].
In patients with very severe aplastic anemia (VSAA), prolonged neutropenia
results in refractory and overwhelming bacterial infections as well as invasive
fungal infections that are associated with significant morbidity and mortality in
these severely immunocompromised individuals [69]. In patients with VSAA
lacking human leukocyte antigen identical sibling donors and having refractory
infections, co-transplantation of haploidentical HSCs and allogeneic BM-MSCs has
been shown to be a safe and a promising therapeutic modality [69].
Studies have shown that: (1) secretion of cathelicidin LL-37 by MSCs could
enhance bacterial products indicating that MSCs can upregulate antimicrobial
activity in the presence of infection and (2) activated MSCs, when administered
intravenously and in combination with conventional antibiotics, can potentially
suppress and eradicate chronic Staphylococcus aureus biofilm infection in difficult-
to-treat locations. Thus, treatment with activated MSCs represents a novel thera-
peutic option for patients having highly drug-resistant infections [44].
5.4 MSCs in bone, joint, and dental infections
The multidirectional differentiation potential of BM-MSCs is essential for tissue
repair after local injury of bones, joints, and medullary adipose tissue. Additionally,
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the regulation of multiple differentiation potentials of MSCs by various antimicro-
bial agents affects the recovery from bone and joint infectious diseases [70].
Minocycline induces the following favorable changes in MSCs: migratory capacity,
proliferation, gene expression, and growth factor release, ultimately resulting in
enhancement of angiogenesis. Also, the triple antimicrobial-loaded hydrogels
reduce bacterial bioburden and preserve viability of MSCs in the presence of
bacteria [71].
Gingival MSCs encapsulated in silver lactate-containing alginate hydrogel have
successfully differentiated into osteogenic tissue and have shown promise for bone
tissue engineering with antimicrobial properties against peri-implantitis caused by
gram negative bacterial infections [72]. Synthesized antibiotic-containing scaffolds
have been shown to possess significantly lower effects on proliferation and viability
of human dental pulp stem cells when compared to the saturated ciprofloxacin/
metronidazole solution [73].
6. MSCs in viral infections
Studies have shown that: (1) MSCs are susceptible to infection by members of
the herpes group of viruses such as: cytomegalovirus, Epstein-Barr virus, herpes
simplex virus (HSV) type 1, HSV-2, and VZV, and MSCs become functionally
defective following infection with herpes viruses; (2) AT-MSCs can differentiate
into functional hepatocyte-like cells but AT-MSCs undergoing hepatic differentia-
tion are not susceptible to infection by hepatitis B virus in vitro; (3) human MSCs
are permissive to the highly pathogenic avian influenza A/H5N1 infection and
infection of MSCs can cause apoptosis and loss of their immunomodulatory activity;
and (4) MSCs can significantly reduce the impairment of alveolar fluid clearance
induced by influenza A/H5N1 infection in vitro and prevent or reduce influenza
A/H5N1-associated ALI in vivo [28, 34, 74]. The extracellular vesicles (ECVs)
secreted by MSCs have anti-inflammatory and anti-influenza properties. Hence,
they can be used as cell-free therapy for influenza in humans [75]. Infection of
MSCs by respiratory syncytial virus (RSV) alters their immunoregulatory functions
by upregulating interferon (IFN)-β and IDO, thus accounting for the lack of pro-
tective RSV immunity and for the chronicity of RSV-associated lung diseases such
as bronchial asthma and chronic obstructive airway disease [76]. In mice models,
treatment with MSCs alleviates inflammation and mortality associated with
Japanese encephalitis virus, which is a leading cause of viral encephalitis in Asia
[77]. Zika virus infection of human MSCs promotes differential expression of pro-
teins that are linked to several neurological disorders such as Alzheimer’s disease,
Parkinson’s disease, autism, and amyotrophic lateral sclerosis [78].
MSCs exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic
properties, and therefore have the potential to improve the outcome of allogeneic
HSCT in patients with AA. In a multicenter study that included 75 patients with AA,
the combination of HSCs obtained from BM and PB sources as well as MSCs has
resulted in amelioration of acute graft versus host disease (GVHD) and viremia
resulting ultimately in an improved survival benefit [79].
6.1 MSCs in HIV infection and AIDS
Acquired immunodeficiency syndrome (AIDS), which is caused by human
immunodeficiency virus (HIV), poses a real threat to human life [80]. Despite the
advent of highly active antiretroviral therapy (HAART) that suppresses plasma
viral load but does not cure disease, HIV-1 persists in latent tissue reservoirs, mainly
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in macrophages and T-helper lymphocytes, and this poses significant challenge to
long-term cure [2, 80–82]. HIV-1 predominantly infects HSCs such as macro-
phages, monocytes, and T-helper lymphocytes [82]. Non-immune responders
(NIRs) do respond to HAART, which effectively suppresses HIV replication, but do
not show any improvement in their immune status as reflected by an increase in
CD4+ T-cell counts [83]. More than 20% of HAART-treated HIV-infected individ-
uals exhibit NIR phenotype and these individuals are at risk of opportunistic infec-
tions, cancer, and reduced life expectancy [83].
Coexposure to MSC-conditioned media can enhance the latency-reactivation
efficacy of the approved latency reversing drugs vorinostat and panobinostat [81].
Undifferentiated AT resident MSCs are not permissive to HIV-1 infection despite
that HIV-1 exposure may increase the expression of some hematopoietic lineage
related genes [82]. It has been reported that transfusions of UCB-MSC or more
specifically WJ are well tolerated and can efficiently improve immune reconstitu-
tion in HIV-infected individuals who are NIRs [83, 84]. Memory CD4 T cells are the
key cells organizing all immune actions against HIV while being the targets of HIV
infection [85]. MSCs can express receptors that permit their infection by HIV-1.
Additionally, human T-lymphotropic virus (HTLV)-1 could infect and replicate in
human BM-MSCs possibly by involvement or infiltration of CD4+ lymphocytes
[2, 86, 87].
7. MSCs in parasitic infections
Recently, MSCs have been introduced to treat parasitic infections associated
with tissue damage in the form of granuloma formation or organ fibrosis such as:
schistosomiasis, malaria, and Chagas disease [88, 89]. Studies have shown that
MSCs can: (1) ameliorate liver injury and hepatic fibrosis induced by Schistosoma
japonicum, particularly when combined with conventional therapies such as
praziquantel and (2) play an important role in improving host protective immune
responses against malaria by modulating regulatory T cells [88, 89].
7.1 MSCs in Chagas disease
Chagas disease, which is caused by the protozoan Trypanosoma cruzi, is endemic
in Central and Latin America. However, incidence of the disease has recently
increased in the United States of America, Canada, Japan, Australia, and Europe due
to migratory movements [2, 90–93]. The disease has acute and chronic phases
[90–92]. The acute phase is characterized by intense parasitemia with no or few
symptoms while the chronic phase, which extends over indeterminate period of
time that may span over years or decades, is characterized by the evolution of
cardiac as well as gastrointestinal manifestations reflecting disease complications
[90, 91]. Pathogenesis of chronic Chagas cardiomyopathy (CMP) is still debatable
but the following have been proposed to be the main pathological mechanisms
involved: parasite persistence, microcirculatory alterations, autoimmune mecha-
nisms, and autonomic dysfunction [90, 94]. The cardiac complications of Chagas
disease include: myocarditis, dilated CMP, heart failure, arrhythmias, heart block,
thromboembolism, stroke, and sudden death [2, 90, 91, 94].
The available and future therapies of Chagas disease include: treatment of
arrhythmias and heart failure, antiparasitic therapy, resynchronization treatment,
heart transplantation, and stem cell therapies [2, 90, 91, 93, 95]. In patients with
chronic Chagas CMP and cardiac failure, conventional pharmacologic therapies are
limited by being not always effective, thus rendering the disease incurable [90, 91, 96].
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Heart transplantationmay occasionally be needed but the procedure has a number of
problems including: shortage of donors, high costs, and complications of long-term
immunosuppressive therapies administered to recipients of heart transplants [90, 95].
Different stem cell types and delivery approaches have been used in both pre-
clinical models as well as clinical trials with the aim of improving cardiac function
and reversing complications [95]. In animal models, stem cell therapies have shown
reductions in: right ventricular dilatation, and inflammatory infiltrates as well as
fibrosis [91, 93]. Stem cell therapy with BM-MSCs has emerged as a novel thera-
peutic option for Chagas CMP and heart failure [91, 93]. In a murine model of
Chagas disease, cotransplantation of autologous BM-MSCs and skeletal myoblasts
has been shown to be effective in reversing ventricular dysfunction [94]. Also, in an
animal model of chronic Chagas disease, genetic modification of MSCs mobilized by
granulocyte colony stimulating factor has increased the immunomodulatory actions
and paracrine functions of MSCs by recruitment of suppressor cells such as regula-
tory T-cells and myeloid-derived suppressor cells [97].
Transplantation of MSCs has shown clinical efficacy in animal or mouse models
but studies in humans have not shown equivalent success due to a number of
challenges that need to be overcome [2, 91, 93, 95, 98]. In animal models of chronic
Chagas CMP, cardiac MSCs have been shown to exert protective effects by
decreasing the degrees of fibrosis and inflammatory infiltrates in the affected myo-
cardium [99]. The beneficial effects of MSC therapy in Chagas mice models may be
an indirect action of the cells on the heart rather than a direct action of the large
numbers of transplanted MSCs on the myocardium [91, 96]. Tracking of infused
BM-MSCs in animal models has shown migration of these cells to the heart and their
participation in tissue repair or regeneration [91–93]. Although an early clinical trial
of intracoronary injection of autologous BM-cells in patients with chronic Chagas
CMP and heart failure showed safety and feasibility, a large multicenter, random-
ized double-blind, placebo-controlled trial using intracoronary infusion of BM-
mononuclear cells showed no improvement in cardiac function or in quality of life
in patients with chronic Chagas CMP [2, 99, 100].
8. MSCs in tuberculosis
Mycobacterium tuberculosis (MTB) remains a leading cause of morbidity and
mortality due to infectious diseases in humans [101]. Multidrug-resistant (MDR)
and extensively drug-resistant (XDR) TB, mainly caused by non-adherence to
antimicrobial therapy, are recognized health problems in: Eastern Europe, South
Africa, and South East Asia [101–103]. Therapeutic strategies that are employed
in the management of MDR/XDR TB include: directly observed treatment
(DOTS), DOTS-Plus, recombinant human IL-2 by aerosol therapy, and
recombinant IFN-γ [102].
Despite the strong host immune response in humans, MTB organisms are capa-
ble of persisting or staying dormant for prolonged periods of time, thus resulting in
latent infection [104–106]. Hypoxia or hypoxemic microenvironment may favor
dormancy of MTB and subsequent evolution of drug resistance [106]. MSCs play a
crucial role in the ability of MTB to evade the potent host immune responses and
cause TB. Hence, targeting MSCs or nitrous oxide (NO) seems a plausible thera-
peutic intervention for the design of new effective preventive strategies against TB
[107]. Studies have shown that MSCs are recruited into the tuberculous granulomas
and they position themselves between the harbored pathogen and the effector T-
cells [107–109]. CD271+ BM-MSCs can provide an antimicrobial protective intra-
cellular niche in the host in which dormant MTB can reside for prolonged periods of
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time [106, 109–111]. MTB infects and persists in a dormant form inside BM-MSCs
even after successful antimicrobial therapy [112]. Virulent mycobacteria can
manipulate Toll-like receptors and certain signaling pathways including nuclear
factor kappa-light-chain-enhancer of activated B cells in order to survive inside the
BM stem cells [112]. MSCs can increase NO production inMycobacterium abscessus-
infected macrophages through activation of tumor necrosis factor (TNF)-α in the
presence of IFN-γ [113]. The cellular crosstalk between TNF-α and prostaglandin-
E2 is essential for the increased production of NO in macrophages [113]. Conse-
quently, MSCs may become an ideal choice as adjunct therapy in MDR and XDR TB
particularly in individuals with comorbid medical conditions [102, 103, 114]. There
are three main clinical trials on the use of MSCs in the treatment of MDR/XDR TB
[115–117]. In the first trial, 27 patients with MDR/XDR TB who had been unsuc-
cessfully treated with conventional anti-TB chemotherapy received autologous
MSCs, the following results were obtained: all patients showed positive responses to
MSC therapy, bacterial discharge from lungs was abolished in 20 patients, tissue
damage and lung cavitation resolved in 11 patients, and persistent remission of TB
was encountered in 56% of patients after 2 years of autologous MSC transplantation
[115]. In the second study, a phase I clinical trial, 36 patients with MDR/XDR TB
received anti-TB chemotherapy for 4 weeks; then, they were subjected to autolo-
gous MSC transplantation [116]. Six months after autologous transplantation of
MSCs: no major adverse events were reported, 70% of patients showed radiological
improvement, while 16.7% of patients showed stable radiological appearances.
Eighteen months after autologous transplantation of MSCs: 53% of patients were
cured, while 10% of patients showed evidence of treatment failure [116]. In the
third study, a randomized clinical trial, 72 patients with MDR/XDR TB were
included: 36 patients (control group) received conventional anti-TB chemotherapy
only, and the other 36 patients (study group) received anti-TB chemotherapy and
autologous MSC transplantation [117]. Successful outcomes were encountered in
81% of the study group and 40% of the control group. So, the addition of autologous
MSC transplantation to conventional anti-TB chemotherapy significantly enhanced
the response rates in patients with MDR/XDR TB [117]. Therefore, combining
standard anti-TB chemotherapy with autologous MSC transplantation may ulti-
mately become valuable in increasing the efficacy of anti-TB treatment in patients
with MDR-TB [2, 102, 115, 116].
9. MSCs in fungal infections
Administration of human MSCs does not have negative impact on host response
against Aspergillus fumigatus [118, 119]. Also, Aspergillus fumigatus does not stim-
ulate MSCs to secrete cytokines that play a major role in the pathogenesis of GVHD
indicating that Aspergillus fumigatus is not involved in the pathogenesis of GVHD
following HSCT. In an animal model, infusion of BM-MSCs into mice infected with
Paracoccidioides brasiliensis failed to induce any antimicrobial effects.
10. Conclusions and future directions
Since their first description in the 1960s, the history of MSCs has witnessed
steady progress that ultimately resulted in their clinical application in the treatment
of many disorders including several infectious diseases. Although the success has
not been uniform with regard to various infections and despite the gap between the
achievements in animal studies and results of clinical trials in humans, plenty of
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efforts have been made to resolve the remaining challenges in the clinical
applications of MSCs in several diseases.
Some of the remaining challenges facing the utilization of MSCs in the clinical
arena include: (1) encountering failure of treatment or resistance to therapy; (2) the
need to have quality control and safety measures; (3) implementation of guidelines
and design of specific protocols for: preparation and manufacture, banking and
cryopreservation of MSC products, administration and therapeutic use of each type
and source of MSCs, and finally tracing of infused MSCs; and (4) performing large
prospective multicenter clinical trials on the use of specific MSCs in certain diseases
in order to test their uniform efficacy and verify their long-term safety.
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